Etiqueta: stem cell research
-
Stem cell therapy maker Aldagen files for IPO
The adult stem cell company Aldagen Inc, from Durham North Carolina announced today that it has filed a registration with the Securities Exchange Commission for an initial public offering with a potential value of $80.5 million.
-
Gilbert Stem Cell Research Programs are Making Healthcare History
Since those early studies which began in Phoenix Arizona in 2000, thousands of patients have been treated with their own stem cells for heart failure.
-
Fat-Derived Adult Stem Cells Targeted for Heart Disease Therapy
In yet another heart disease study, adult stem cells derived from adipose tissue are chosen as the most promising therapy.
-
Adult Stem Cells Treat Cerebral Palsy
The XCell-Center in Germany reports positive clinical results from 45 cerebral palsy patients who were treated with autologous adult stem cells derived from bone marrow, in whom 67% improved as a result of the treatment.
-
Stem Cell Awareness Day Events Planned in California
Among other places, the University of California at Merced is observing Stem Cell Awareness Day with a series of events on campus that highlight the latest developments in the field.
-
Adult Stem Cells Used in Clinical Trial for Heart Failure
The U.S. adult stem cell company Bioheart has announced positive results from its clinical trial in the treatment of heart failure with adult stem cells.
-
Stem Cell Pioneers Honored at Lasker Awards
Among this year’s recipients of the Lasker Awards are Dr. Shinya Yamanaka of Kyoto University in Japan and Dr. John Gurdon of Cambridge University in England.
-
Neuralstem Awarded Adult Stem Cell Patent
The U.S. company Neuralstem receives yet another patent for its novel adult stem cell technology.
-
Horse Benefits From Adult Stem Cells
Once again, applications of adult stem cell therapy in veterinary medicine continue to race ahead of human medicine.
-
Adult Stem Cell Company Reports on Heart Therapy
The adult stem cell company Cardio3 BioSciences presents an update on its heart failure therapy at the annual conference of the European Society of Cardiology.